Midi Health Review

Midi Health is a virtual clinic for perimenopause and menopause that does something most menopause telehealth does not: it bills your insurance. Where the category standard is a monthly subscription and a cash-pay prescription, Midi runs as a clinical practice, in-network with most PPO plans, in all 50 states.

That single design choice drives everything else about the platform, including the parts that frustrate people. Visits are real appointments rather than questionnaires. Labs can be ordered. And the price you will actually pay cannot be quoted in advance, because it depends on a plan Midi does not control.

Scorecard

What you get for the money

A Midi first visit runs 30 minutes. The clinician works through symptoms, health history and goals, then builds a care plan. Follow-ups run 15 minutes and exist to track what is working and adjust what is not, and Midi states you can book them as often as you need rather than on a fixed schedule.

Care plans can include hormone prescriptions such as HRT patches, estradiol cream and progesterone, vaginal estrogen for genitourinary symptoms, non-hormone prescriptions, and GLP-1 medications. Some products can be handled through a short asynchronous visit; others require the full appointment. Midi also sells supplements and a skincare product directly, which are optional and separate from the clinical relationship.

Testing is available but not automatic. Midi states it may order labs to understand the full picture, naming a metabolic panel, thyroid testing and insulin-sensitivity markers. Bloodwork generally goes through Labcorp because of its drop-in network, and can be ordered elsewhere on request. Labs are billed separately from the visit.

What it costs

Self-pay is the only path with a knowable total. Two visits in a year, one initial and one follow-up, cost $400. Three visits cost $550. There is no membership fee layered on top, which distinguishes Midi from most of the category.

The insured path is cheaper for most people who qualify and genuinely unpredictable for all of them. An in-network PPO visit against a met deductible can cost a standard specialist copay. The same visit early in a plan year, against an unmet deductible, can cost the full contracted rate. Midi is explicit that deductibles, coinsurance and copays vary and may still apply, which is accurate rather than evasive, but it means nobody can quote your number except your insurer.

Coverage, and where it stops

Midi names Aetna, Blue Cross Blue Shield, Cigna, Health Net and UnitedHealthcare as insurance partners and states it is in-network with most PPO plans. The exclusions are stated just as plainly: Medicare is out of network, and Midi is not able to accept Medicaid or Medi-Cal patients. HSA and FSA funds can be used for visits and services.

Two gaps follow from that, and both hit exactly the populations menopause care most often fails. Anyone on Medicare is outside the network, whether enrolled by age or by disability. Women on Medicaid cannot be seen at all. For both groups, the self-pay rate of $250 and $150 is the only available price, which is a real cost for care that a traditional in-network gynecologist might cover.

Clinicians and clinical approach

Midi's clinicians are board-certified nurse practitioners, certified nurse midwives, physicians and naturopathic doctors specializing in women's midlife health. Several hold Menopause Society certification, and Midi publishes individual clinician profiles listing those credentials. Midi states its protocols are evidence-based and informed by current literature and guidelines from ACOG, the AMA, ISSWSH, The Menopause Society, the NCCN and The Obesity Association.

Naming the NCCN alongside the menopause bodies is not decorative. Cancer survivorship is one of the harder problems in this field, because a history of estrogen-sensitive cancer changes which options are on the table, and it is a conversation many general practices avoid entirely. A practice that cites oncology guidance is signaling that it intends to have that conversation rather than decline it. Whether any individual clinician is the right one for a complex history is still a question to ask directly at the first visit.

Company-reported results

Midi states it has served more than 450,000 women and reports that 95% of patients report peri/menopause symptom improvement after at least two months. Both figures are company-reported rather than independently audited, and the second has no published denominator, follow-up period or definition of improvement attached. Treat it as a marketing claim, not as trial data. The evidence that matters for your decision is the underlying literature on hormone therapy, which is independent of any platform.

Public litigation

A search of the federal court docket in August 2026 returned two civil suits naming Midi Health, Inc., both pending in the U.S. District Court for the Northern District of California: N.C. v. Midi Health, Inc. (No. 5:25-cv-02848, filed March 26, 2025) and Baker v. Midi Health, Inc. (No. 5:25-cv-10414, filed December 4, 2025). Neither has been decided, and a filed complaint contains allegations rather than findings. Midi's own published terms include an arbitration notice and class-action waiver, which is worth reading before you sign up.

Strengths

• Insurance actually pays for the visit. In-network status with most PPO plans, including five named national insurers, moves the largest controllable line onto the plan.
• Diagnosis is on the table, not just prescription. Thyroid, metabolic and insulin-sensitivity testing can be ordered when the picture is unclear.
• A real appointment. Thirty minutes of clinician time allows a history and a contraindication discussion that no intake form replaces.
• Specialist credentials, published. Menopause Society certification is held by multiple clinicians and listed on individual profiles.
• Nationwide, with no subscription. All 50 states, pay per visit, prescriptions to the pharmacy of your choice.

Trade-offs

• Your price is unknowable in advance. Deductible, coinsurance and copay decide it, and none of them are visible at booking.
• Medicare and Medicaid are excluded. Two of the populations most likely to need affordable menopause care are outside the model.
• Three separate bills. Visit, labs and pharmacy arrive from different places at different times.
• Testing is discretionary. Labs are ordered when indicated, so a woman who wants a defined baseline panel has to ask for it rather than expect it.
• Two undecided civil suits. Both pending in N.D. Cal., alongside published terms containing an arbitration notice and class-action waiver.

How it compares

Menopause-specialist platforms, listed alphabetically. Ordering carries no editorial meaning.

The split in this category is not really about price, it is about which half of the bill each platform optimizes. Cash-pay services set the medication price and charge little to be seen. Midi sets the visit price, or lets your insurer set it, and leaves the medication to your pharmacy. Compare a full year of both halves, not the headline number, and check your pharmacy benefit before deciding either way.

Who should buy it, and who should not

Buy it if you have a PPO plan and unexplained midlife symptoms. Fatigue, weight change, poor sleep and brain fog overlap almost completely with thyroid disease and iron deficiency, both of which are common in this age group and both of which get missed when a platform only prescribes. A clinician who can order the test and read it against the hormone question is worth the visit fee even if the answer turns out to be hormonal after all.

Skip it if you are uninsured, on Medicare or Medicaid, or have already made the decision. If you know you want a transdermal estradiol patch and micronized progesterone, and your thyroid and iron picture is current and normal, you are paying for a diagnostic conversation you do not need. A cash-pay prescribing route reaches the same prescription faster and at a price you can see up front.

Before your first visit

Four things make the appointment more useful. Run your insurance through the coverage check on Midi's site rather than assuming, since plan type matters more than insurer name. Bring your last lab results if you have any, so the clinician is not starting from zero. Write down your cycle history, including dates, because perimenopause is diagnosed clinically from that pattern rather than from a single hormone value. And list every medication and supplement you take, since several interact with hormone therapy.

Ask two questions at the visit. Which labs are you ordering, and is each one covered by my plan. And which specific product and delivery route are you proposing, since a patch, a gel and an oral tablet differ in cost and in clotting risk. Neither question is confrontational, and both prevent the bills that arrive later.

Related

• Alloy vs Midi Health
• Midi Health cost breakdown
• Hormone therapy platforms compared on one rubric
• Perimenopause biomarker panel
• HRT side effects and risks
• All doctor-led options compared